EP0696194B1 - Utilisation de derives d'indoles comme antagonistes de 5ht1 - Google Patents

Utilisation de derives d'indoles comme antagonistes de 5ht1 Download PDF

Info

Publication number
EP0696194B1
EP0696194B1 EP94912048A EP94912048A EP0696194B1 EP 0696194 B1 EP0696194 B1 EP 0696194B1 EP 94912048 A EP94912048 A EP 94912048A EP 94912048 A EP94912048 A EP 94912048A EP 0696194 B1 EP0696194 B1 EP 0696194B1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
indole
methylaminosulfonylmethyl
ylmethyl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP94912048A
Other languages
German (de)
English (en)
Other versions
EP0696194A1 (fr
Inventor
John Eugene Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0696194A1 publication Critical patent/EP0696194A1/fr
Application granted granted Critical
Publication of EP0696194B1 publication Critical patent/EP0696194B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to pharmaceutical compositions containing indole derivatives and to their medicinal use.
  • the active compounds of the present invention are useful in treating migraine and other disorders.
  • United States Patents 4,839,377 and 4,855,314 and European Patent Application Publication Number 313397 refer to 5-substituted 3-aminoalkyl indoles. The compounds are said to be useful for the treatment of migraine.
  • British Patent Application 040279 refers to 3-aminoalkyl-1H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension, Raymond's disease and migraine.
  • European Patent Application Publication Number 303506 refers to 3-poly:hydro-pyridyl-5-substituted-1H-indoles. The compounds are said to have 5HT 1 -receptor agonist and vasoconstrictor activity and to be useful in treating migraine.
  • European Patent Application Publication Number 354777 refers to N-piperidinyl:indolyl:ethyl-alkane sulfonamide derivatives.
  • the compounds are said to have 5HT 1 -receptor agonist and vasoconstrictor activity and to be useful in treating cephalic pain.
  • the present invention relates to pharmaceutical compositions and methods of use of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole and (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-lH-indole (hereinafter also referred to as the active indoles).
  • the present invention relates to a pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound of the active indoles or a pharmaceutically acceptable salt thereof effective in treating such condition and a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission (e.g., depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders) comprising an amount of a compound of the active indoles or a pharmaceutically acceptable salt thereof effective in treating such condition and a pharmaceutically acceptable carrier.
  • deficient serotonergic neurotransmission e.g., depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders
  • the present invention also relates to a method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders.
  • the present invention also relates to a method for treating disorders arising from deficient serotonergic neurotransmission.
  • the active indoles used in the present invention can be prepared using the methods disclosed in International Publication No. WO 92/06973.
  • the active indoles are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate an active indoles from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the active indoles are readily prepared by treating the compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the active indoles are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
  • non-toxic acid addition salts i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphat
  • the active indoles and the pharmaceutically acceptable salts thereof are useful psychotherapeutics and are potent serotonin (5-HT 1 ) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, chronic paroxysmal hemicrania and headache associated with vascular disorders, pain, and other disorders arising from deficient serotonergic neurotransmission.
  • the compounds can also be used as centrally acting antihypertensives and vasodilators.
  • the active compounds of the invention are evaluated as anti-migraine agents by testing the extent to which they mimic sumatriptan in contracting the dog isolated saphenous vein strip (P.P.A. Humphrey et al., Br . J . Pharmacol. , 94 , 1128 (1988)). This effect can be blocked by methiothepin, a known serotonin antagonist. Sumatriptan is known to be useful in the treatment of migraine and produces a selective increase in carotid vascular resistance in the anaesthetized dog. It has been suggested (W. Fenwick et al., Br . J . Pharmacol. , 96 , 83 (1989)) that this is the basis of its efficacy.
  • the active compounds of the present invention are also evaluated as anti-migraine agents via the inhibition of plasma protein extravasation response within the dura mater of guinea pigs following unilateral electrical trigeminal ganglion stimulation.
  • the extent to which they mimic sumatriptan, in terms of both potency and efficacy, is determined in this assay.
  • the procedure is performed on male Hartley guinea pigs (200-250 g, Charles River Laboratories, Wilmington, MA, U.S.A.) as described in Markowitz et al., J. Neurosci ., 7 (12), 4129-4136 (1987) and also in Lee, et al., Brain Reseach, 626, 303-305 (1993).
  • the procedure briefly consists of placing pentobarbitone-anesthetized animals in a stereotaxic frame.
  • 125 I-BSA bovine serum albumin
  • Bipolar electrodes are then lowered into the trigeminal ganglia, and the right ganglion is stimulated for 5 minutes (1.2 nA, 5 Hz, 5 msec).
  • the animal is then perfused with saline through the left cardiac ventricle and sacrificed, and the dura mater is dissected, weighed, and counted for radioactivity.
  • Cpm/mg wet weight values are determined for the right vs left dura mater, and a ratio for the stimulated vs unstimulated sides is generated for each animal. Unpaired student's t-test is used to statistically compare these ratio values in respective groups treated with vehicle or drug.
  • the M.E.D. (minimally effective dose) for a given compound is the lowest dose for which the mean value of this ratio is significantly lower than that obtained for the vehicle-treated group.
  • the effect of the drugs in these assays can be partially blocked by metergoline, a known serotonin antagonist.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
  • the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) ; fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non-aqueous vehicles e.g. almond oil, oily esters or ethyl alcohol
  • preservatives e.g
  • composition may take the form of tablets or lozenges formulated in conventional manner.
  • the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartriges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • a proposed dose of the compound (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., migraine) is 0.1 ⁇ g to 0.09 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • the pharmaceutical composition includes 0.5 ⁇ g to 0.09 mg of the active ingredient per unit dose.
  • a proposed dose of the compound (R)-5-(methylaminosulfoylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., migraine) is 0.01 ⁇ g to 0.09 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • the pharmaceutical composition includes 0.05 ⁇ g to 0.09 mg of the active ingredient per unit dose.
  • Aerosol formulations for treatment of the conditions referred to above are preferably arranged so that each metered dose or "puff" of aerosol contains 0.01 ⁇ g to 19 ⁇ g of either of the compounds (R)-5-(methylaminosulfonylmethyl)-3-(N-methyl-pyrrolidin-2-ylmethyl)-1H-indole or (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole.
  • each metered dose or "puff" of aerosol contains 0.05 ⁇ g to 19 ⁇ g of the active ingredient.
  • the overall daily dose with an aerosol will be within the range 0.05 ⁇ g to less than 100 ⁇ g. In one embodiment, the overall daily dose with an aerosol will be within the range 0.05 ⁇ g to 99 ⁇ g of the active ingredient. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
  • Chromatography refers to column chromatography performed using 32-63 ⁇ m silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room temperature refers to 20 - 25°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (9)

  1. Composition pharmaceutique pour l'administration orale, parentérale, buccale ou rectale, comprenant une quantité de (R)-5-(méthylaminosulfonylméthyl)-3-(N-méthylpyrrolidine-2-ylméthyl)-1H-indole ou d'un de ses sels pharmaceutiquement acceptables allant de 0,1 µg à 0,09 mg et un support pharmaceutiquement acceptable.
  2. Composition pharmaceutique pour l'administration orale, parentérale, buccale ou rectale, comprenant une quantité de (R)-5-(méthylaminosulfonylméthyl)-3-(pyrrolidine-2-ylméthyl)-1H-indole ou d'un de ses sels pharmaceutiquement acceptables allant de 0,01 µg à 0,09 mg et un support pharmaceutiquement acceptable.
  3. Composition suivant la revendication 1, dans laquelle la quantité va de 0,5 µg à 0,09 mg.
  4. Composition suivant la revendication 2, dans laquelle la quantité va de 0,5 µg à 0,09 mg.
  5. Composition pharmaceutique suivant l'une quelconque des revendications précédentes, qui est sous forme d'un comprimé, d'une capsule, d'un suppositoire, d'un lavement à garder ou d'une dose unitaire pour l'injection.
  6. Composition pharmaceutique pour l'administration en aérosol, comprenant une quantité de (R)-5-(méthylaminosulfonylméthyl)-3-(N-méthylpyrrolidine-2-ylméthyl)-1H-indole ou (R)-5-(méthylaminosulfonylméthyl)-3-(pyrrolidine-2-ylméthyl)-1H-indole, ou d'un de ses sels pharmaceutiquement acceptables, comprise dans l'intervalle de 0,01 µg à 19 µg par dose mesurée, et un support pharmaceutiquement acceptable.
  7. Composition suivant la revendication 6, dans laquelle la quantité est comprise dans l'intervalle de 0,05 µg à 19 µg.
  8. Utilisation d'une composition suivant l'une quelconque des revendications précédentes pour la production d'un médicament destiné au traitement d'une affection choisie entre l'hypertension, la dépression, l'anxiété, des troubles de l'alimentation, l'obésité, la dépendance de médicaments, les céphalées vasculaires de Horton, la migraine, la douleur, l'hémicranie paroxystique chronique et les céphalées associées à des troubles vasculaires.
  9. Utilisation d'une composition suivant l'une quelconque des revendications 1 à 7 pour la production d'un médicament destiné au traitement d'une affection provenant d'une neurotransmission sérotoninergique déficiente.
EP94912048A 1993-04-27 1994-04-26 Utilisation de derives d'indoles comme antagonistes de 5ht1 Expired - Lifetime EP0696194B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5393093A 1993-04-27 1993-04-27
US53930 1993-04-27
PCT/IB1994/000079 WO1994025023A1 (fr) 1993-04-27 1994-04-26 Utilisation de derives d'indoles comme antagonistes de 5ht1

Publications (2)

Publication Number Publication Date
EP0696194A1 EP0696194A1 (fr) 1996-02-14
EP0696194B1 true EP0696194B1 (fr) 2002-08-21

Family

ID=21987528

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94912048A Expired - Lifetime EP0696194B1 (fr) 1993-04-27 1994-04-26 Utilisation de derives d'indoles comme antagonistes de 5ht1

Country Status (29)

Country Link
EP (1) EP0696194B1 (fr)
JP (1) JP2922307B2 (fr)
KR (1) KR960701636A (fr)
CN (3) CN1509713A (fr)
AP (1) AP486A (fr)
AT (1) ATE222492T1 (fr)
AU (1) AU689469B2 (fr)
BG (1) BG61898B1 (fr)
BR (1) BR9406435A (fr)
CA (1) CA2161533C (fr)
CO (1) CO4230093A1 (fr)
CZ (1) CZ290416B6 (fr)
DE (1) DE69431201T2 (fr)
DK (1) DK0696194T3 (fr)
ES (1) ES2180573T3 (fr)
HU (1) HU222488B1 (fr)
IL (1) IL109376A (fr)
MX (1) MX9403088A (fr)
NO (1) NO308236B1 (fr)
NZ (1) NZ263614A (fr)
OA (1) OA10189A (fr)
PL (1) PL175156B1 (fr)
PT (1) PT696194E (fr)
RO (1) RO117760B1 (fr)
RU (1) RU2132683C1 (fr)
SG (1) SG43951A1 (fr)
SK (1) SK283353B6 (fr)
WO (1) WO1994025023A1 (fr)
ZA (1) ZA942805B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
JP2860603B2 (ja) * 1993-08-31 1999-02-24 ファイザー・インク． ５−アリールインドール誘導体
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
PT804433E (pt) * 1994-10-12 2002-12-31 Pfizer Res & Dev Derivado de indole para o tratamento da enxaqueca
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
US5773015A (en) * 1996-11-27 1998-06-30 Elizabeth Arden Co., Division Of Conopco, Inc. Method for controlling skin oils and grease
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
ES2199086B1 (es) * 2002-07-31 2005-06-01 Cepa Schwarz Pharma Sl Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
KR20220137085A (ko) * 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592438B1 (fr) * 1990-10-15 1997-08-27 Pfizer Inc. Derives d'indole
GB9102579D0 (en) * 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
GB9103770D0 (en) * 1991-02-22 1991-04-10 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU689469B2 (en) 1998-04-02
ZA942805B (en) 1995-10-23
WO1994025023A1 (fr) 1994-11-10
ATE222492T1 (de) 2002-09-15
OA10189A (en) 1996-12-18
KR960701636A (ko) 1996-03-28
HUT73670A (en) 1996-09-30
DE69431201D1 (de) 2002-09-26
AP9400633A0 (en) 1994-04-30
HU9503089D0 (en) 1995-12-28
EP0696194A1 (fr) 1996-02-14
BG100093A (bg) 1996-04-30
RU2132683C1 (ru) 1999-07-10
AU6436094A (en) 1994-11-21
IL109376A0 (en) 1994-07-31
CZ290416B6 (cs) 2002-07-17
ES2180573T3 (es) 2003-02-16
HU222488B1 (hu) 2003-07-28
IL109376A (en) 2000-10-31
CN1515252A (zh) 2004-07-28
CZ9502802A3 (en) 1996-04-17
CO4230093A1 (es) 1995-10-19
PT696194E (pt) 2002-11-29
SK133295A3 (en) 1997-01-08
MX9403088A (es) 1997-02-28
RO117760B1 (ro) 2002-07-30
CN1509713A (zh) 2004-07-07
NO954287L (no) 1995-10-26
NZ263614A (en) 1998-02-26
PL311266A1 (en) 1996-02-05
PL175156B1 (pl) 1998-11-30
NO954287D0 (no) 1995-10-26
DE69431201T2 (de) 2002-12-05
BR9406435A (pt) 1996-01-09
BG61898B1 (bg) 1998-09-30
SG43951A1 (en) 1997-11-14
CN1121689A (zh) 1996-05-01
CA2161533C (fr) 1998-08-04
SK283353B6 (sk) 2003-06-03
NO308236B1 (no) 2000-08-21
CA2161533A1 (fr) 1994-11-10
DK0696194T3 (da) 2002-10-07
JP2922307B2 (ja) 1999-07-19
AP486A (en) 1996-04-16
JPH08504829A (ja) 1996-05-28

Similar Documents

Publication Publication Date Title
EP0696194B1 (fr) Utilisation de derives d'indoles comme antagonistes de 5ht1
US6512002B2 (en) Methods of treatment for premature ejaculation in a male
EP0839040B1 (fr) Utilisation d'inhibiteurs de phosphodiesterase specifique de gmpc dans le traitement de l'impuissance
WO1994025023A9 (fr) Utilisation de derives d'indoles comme antagonistes de 5ht1
JPH09508137A (ja) セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
GB2208646A (en) Indole derivatives
IL87658A (en) Tetrahydro-H-) -12-imidazolylmethyl (pyrido-) and azapino- (] B) -4,3 ([indole-1-ointments, their preparation and pharmaceutical preparations containing them
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
WO1998027089A1 (fr) Composes du 5-alkyl-indole utilises comme ligands de type 5-ht¿1d?
JPH02167280A (ja) ラクタム誘導体
EP0804433B1 (fr) Derive indole destine au traitement de la migraine
JPS6335570A (ja) ヘテロ環式化合物
US5945118A (en) Indole derivative for the treatment of migraine
JPH02180824A (ja) 医薬
AU627770B2 (en) The use of lactam derivatives in the treatment of depression
US5229407A (en) Medicaments
JPH02180823A (ja) 医薬
US5221687A (en) Medicaments
JPH07503240A (ja) ３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用
EP0411901A2 (fr) Traitement des états poussant à une alimentation excessive

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19990202

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/40 A, 7A 61P 9/12 B, 7A 61P 25/06 B, 7A 61P 25/24 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

REF Corresponds to:

Ref document number: 222492

Country of ref document: AT

Date of ref document: 20020915

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69431201

Country of ref document: DE

Date of ref document: 20020926

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20020920

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20020403361

Country of ref document: GR

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2180573

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030522

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050314

Year of fee payment: 12

Ref country code: DK

Payment date: 20050314

Year of fee payment: 12

Ref country code: AT

Payment date: 20050314

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050316

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050401

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050404

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20050406

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20050414

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20050421

Year of fee payment: 12

Ref country code: ES

Payment date: 20050421

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050428

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050429

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20050603

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050613

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060426

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060426

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060427

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060430

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060430

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061101

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061101

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060426

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20061026

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20061101

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20061230

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060427

BERE Be: lapsed

Owner name: *PFIZER INC.

Effective date: 20060430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070426